In Vivo Gene Delivery in the Retina Using Polyethylenimine
2007; Future Science Ltd; Volume: 42; Issue: 3 Linguagem: Inglês
10.2144/000112404
ISSN1940-9818
Autores Tópico(s)CRISPR and Genetic Engineering
ResumoBioTechniquesVol. 42, No. 3 BenchmarksOpen AccessIn vivo gene delivery in the retina using polyethylenimineHsi-Wen Liao & King-Wai YauHsi-Wen LiaoJohns Hopkins University School of Medicine, Baltimore, MD, USA & King-Wai YauJohns Hopkins University School of Medicine, Baltimore, MD, USAPublished Online:16 May 2018https://doi.org/10.2144/000112404AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail Virus-based methods are widely used in the mammalian nervous system for expressing genes (1) and for producing short hairpin RNAs (shRNAs) (2) to knock down genes by RNA interference (RNAi). In the latter case, only a percentage of the small interfering RNAs (siRNAs) can effectively silence their cognate target genes (3). Thus, multiple selections of siRNA are often required. This multiplicity can make the virus-based method time-, labor-, or cost-intensive, especially when compounded with the goal of targeting multiple genes. Also, not all neuronal types are susceptible targets of a viral carrier. For example, retinal ganglion cells (RGCs) are known so far to be readily transduced only by adeno- associated virus and lentiviruses (4–6). Here, we report the successful use of a polymer as a carrier to deliver shRNA- expressing plasmid DNA to these cells in vivo.Nonviral carriers such as polymers are simple to use and can be safer than viral carriers. The cationic polymer polyethylenimine (PEI) has been used for transfection in vitro and in vivo mostly of non-neuronal tissues (7). We tested the efficiency of PEI/DNA polyplexes for transfecting RGCs in vivo, so chosen because these cells are adjacent to the vitreous and therefore are likely accessible to the polyplexes delivered by intravitreal injection.A commercial vector (RNAi-Ready pSIREN-DNR-DsRed-Express; Clontech, Mountain View, CA, USA) expressing shRNA (driven by a human U6 promoter) and a reporter Discosoma red fluorescent protein (DsRed) [driven by a cytomegalovirus (CMV) promoter] was mixed with PEI (in vivo-jetPEI™; Polyplus Transfection, Illkirch, France) according to the manufacturer's instructions. In this study, the N:P ratio (i.e., the number of nitrogen residues of in vivo-jetPEI per DNA phosphate) used was 10 (e.g., 1 µg DNA was mixed with 0.2 µL in vivo-jetPEI). The PEI/DNA polyplex solution (1.2 µL for each eye) was carefully administered intravitreally (Figure 1A) from the posterior-temporal side of the eye of an anesthetized mouse via a no. 33 custom needle (1-inch-long/sharp point/type no. 2; Hamilton, Reno, NV, USA) on a 2.5-µL Hamilton syringe. The resulting expression of DsRed was evident in many cells in the ganglion cell layer (Figure 1B). In the retinal cross-section, DsRed expression was confirmed to be in the ganglion cell layer, indicating that the intravitreally injected polyplexes were able to cross the optic nerve fiber layer (containing the axons of the ganglion cells) from the vitreous (Figure 1C).Figure 1. In vivo polymer-mediated gene delivery in retina.(A) Intravitreal injection of polyethylenimine (PEI)/DNA polyplexes. The short hairpin RNA (shRNA)- and Discosoma red fluorescent protein (DsRed)-expressing plasmid DNA was mixed with PEI and administered to the intravitreal space of mouse eyes. (B) Transfected cells (5 days after injection) expressing DsRed (red) in the ganglion cell layer of a flat-mounted, paraformaldehyde-fixed mouse retina. (C) Cross-sectional view of another transfected retina, confirming that the transfection (red) was confined to the ganglion cell layer. Ten retinas (from five animals) were examined in total. Red, DsRed; blue, 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; CMV, cytomegalovirus.We next examined the shRNA expression. We designed the shRNA to target melanopsin (8), the photopigment mediating the light response of the intrinsically photosensitive RGCs (ipRGCs) (9,10). The intrinsic photosensitivity of the ipRGCs is required in order for the pupillary light reflex to reach completion at high irradiances, with melanopsin-knockout mice showing an incomplete pupil restriction in bright light (9). We hypothesized that knocking down melanopsin in the wild-type mouse retina should produce a similar phenotype. We chose an albino background (Balb/c) because the pupil size of melanopsin-knockout mouse with this background (B6.129.Balb/c) at high irradiances was significantly larger than that with a pigmented background (B6.129; unpublished observation). The underlying mechanism for this difference is unclear, but may reflect multiple defects associated with the albino locus, including abnormal axonal projections from the eye to the brain, an underdeveloped central retina, and a deficit of the rod system (11). The pupil reflex in an albino background thus gave a more dramatic indication of melanopsin knockdown. In Figure 2A, immunohistochemistry with a melanopsin antibody (12) indicated that melanopsin expression in the transfected (DsRed positive) area was reduced to an undetectable level by the melanopsin-specific shRNA. In the untransfected (DsRed negative) area of the same retina, melanopsin expression was normal. The eyes injected with melanopsin-shRNA-expressing plasmid DNA showed an incomplete pupil constriction in bright light (10,000 lux), whereas the eyes injected with control DNA were unaffected (Figure 2, B and C). The variation in pupil constriction from eye to eye due to melanopsin-specific shRNA (Figure 2C) conceivably resulted from the variation in the size of the transfected area. Over the entire retina, the average number of remaining melanopsin-immunoreactive cells (all found outside the transfected area) at 5 days after transfection was 176 ± 28 (mean ± sem; 12 retinas from 6 animals), which translated to 25% ± 4% of the total melanopsin-espressing RGCs (MOP-RGCs) (12). Thus, the average transfected area was 75% ± 4% (mean ± sem). The variation in the transfected area presumably reflects the technically challenging intravitreal injection into the very limited space between the retina and the lens in mouse. In other mammals, including primates, the intra-vitreal injection should be considerably easier. Part of the variation in pupil size, which has autonomic input from the nervous system (9), could also have come from the animal's stress level during handling (13). Nonetheless, the melanopsin-knockdown effect was clear. The DsRed expression and the melanopsin-knockdown effect started to appear as early as 16 h after injection and lasted at least 2 months (Figure 2D).Figure 2. Melanopsin short hairpin RNA (shRNA) abolished melanopsin expression in transfected area of retina and decreased pupillary light reflex at high irradiances.(A) Confocal images of a flat-mounted mouse retina immunostained for melanopsin at 5 days after injection of melanopsin shRNA-expressing plasmid DNA. The expression (green) of the melanopsin protein was normal in intrinsically photosensitive retinal ganglion cells (ipRGCs; arrow heads) in the untransfected area, but absent in the transfected area (red). Ten retinas (from five animals) were examined. The red is Discosoma red fluorescent protein (DsRed). The green used was Alexa Fluor® 488-conjugated secondary antibody (Molecular Probes; Invitrogen, Carlsbad, CA, USA). The sequences used for melanopsin shRNA were: 5′-ACGGTCATCTACACCTTCT-3′, 5′-ATCATCAACCTCGCAGTCA-3′, 5′-CCATTATCTACGCCATCAC-3′, and 5′-CCTAGAAGATGGAGAACTC-3′. All four were effective in knocking down melanopsin expression. The results shown in this panel were obtained with the first sequence. (B) Examples of pupil constriction at high irradiances (10,000 lux) of albino eyes injected with either control (left) or melanopsin (right) shRNA-expressing DNA construct at 5 days after injection. Arrow heads mark the boundary of pupil. The eye injected with melanopsin shRNA-expressing DNA construct showed a much more dilated pupil in bright light. The sequences used for control shRNA were for rod transducin: 5′-CATCATCTACGGCAACACT-3′ and 5′-CGCTCAACATTCAGTATGG-3′; for cone transducin: 5′-AGGAAGCCAAGACTGTCAA-3′ and 5′-GGAAGAGCACTATCGTCAA-3′. Only one construct was injected to a given eye, and the collected results in panel C were pooled from all constructs. Both eyes of each mouse were injected with polyethylenimine (PEI)/DNA polyplexes. The measurements of pupil constriction were carried out 5 days after injection to allow enough time for the wounds caused by the injection to heal and the RNA interference (RNAi) to take effect. For some mice, measurements were also made at different time points to study the time course of the RNAi effect. Before the measurement of pupil constriction, the mice were kept in a 14/10 light/dark cycle. In room light (approximately 250–350 lux), a mouse (without anesthesia) was held by hand behind an opaque screen with a hole (slightly larger than the eye) at the center. The eye to be measured was placed against the hole to receive a steady intense light stimulus (10,000 lux; tungsten incandescent bulb, unfiltered) from the other side of the screen; the other eye (not stimulated by the bright light) remained exposed to room light. A photograph of the stimulated eye was taken 5–8 s after stimulus onset (when the pupil constriction had stabilized). Next, the other eye was stimulated and photographed similarly. The pupil size on the photograph was later measured manually using Adobe® Photoshop®. The pupil reflex is bilaterally controlled (12,16,17), so in principle, the eye unstimulated by the intense light but still exposed to the room light would contribute to the pupil constriction. However, the light intensity required for full pupil constriction far exceeded that of the room light. (C) Collective data of pupillary light reflex at high irradiances. Thirty-six eyes (18 animals) were used in each of the control shRNA and the melanopsin shRNA groups. The circles indicate measurements from individual eyes; bars indicate averages ± standard errors. The asterisk indicates that the P value of the Student's t-test <0.001. The blue dotted line marks the average pupil size of uninjected albino mice in the same light condition. (D) Long-lasting effect of melanopsin shRNA. The measurements were stopped at 2 months, while the knockdown effect still showed no sign of decrease. Six eyes (three animals) were used in each of the control shRNA (first sequence for rod transducin described above) and the melanopsin shRNA (first sequence for melanopsin) groups. Error bar, mean ± sem.We thus have demonstrated a fast and simple nonviral method using a polymer for delivering DNA to RGCs. From sequence design to injection, it can be as fast as a few days in the case of an RNAi experiment involving even multiple constructs. Recently, it has been shown possible to restore retinal photosensitivity in mice that have degenerated rods and cones by the virus-mediated expression of channelrhodopsin, a photosensitive ion channel, in RGCs (14). Thus, there is considerable research interest in vision reviving gene therapy involving these cells. The current method provides a simple alternative approach. Conceivably, with injection into the subretinal space, the same method can be used for gene delivery to the rods and cones, another active area of research on ameliorating loss of vision associated with defects in rod/cone function (15). As mentioned earlier, the polymer method becomes particularly expedient when the deliveries of many DNA constructs have to be tested or made.AcknowledgmentsWe thank members of the Yau laboratory for helpful comments on the manuscript. This work was supported by grant no. EY14596 from the U.S. National Institutes of Health (NIH).Competing Interests StatementThe authors declare no competing interests.References1. Young, L.S., P.F. Searle, D. Onion, and V. Mautner. 2006. Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 208:299–318.Crossref, Medline, CAS, Google Scholar2. Raoul, C., S.D. Barker, and P. Aebischer. 2006. Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther. 13:487–495.Crossref, Medline, CAS, Google Scholar3. Reynolds, A., D. Leake, Q. Boese, S. Scaringe, W.S. Marshall, and A. Khvorova. 2004. Rational siRNA design for RNA interference. Nat. Biotechnol. 22:326–330.Crossref, Medline, CAS, Google Scholar4. Dudus, L., V. Anand, G.M. Acland, S.J. Chen, J.M. Wilson, K.J. Fisher, A.M. Maguire, and J. Bennett. 1999. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res. 39:2545–2553.Crossref, Medline, CAS, Google Scholar5. Martin, K.R., R.L. Klein, and H.A. Quigley. 2002. Gene delivery to the eye using adeno-associated viral vectors. Methods 28:267–275.Crossref, Medline, CAS, Google Scholar6. van Adel, B.A., C. Kostic, N. Deglon, A.K. Ball, and Y. Arsenijevic. 2003. Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time. Hum. Gene Ther. 14:103–115.Crossref, Medline, CAS, Google Scholar7. Lungwitz, U., M. Breunig, T. Blunk, and A. Gopferich. 2005. Polyethyleniminebased non-viral gene delivery systems. Eur. J. Pharm. Biopharm. 60:247–266.Crossref, Medline, CAS, Google Scholar8. Provencio, I., G. Jiang, W.J. De Grip, W.P. Hayes, and M.D. Rollag. 1998. Melanopsin: an opsin in melanophores, brain, and eye. Proc. Natl. Acad. Sci. USA 95:340–345.Crossref, Medline, CAS, Google Scholar9. Lucas, R.J., S. Hattar, M. Takao, D.M. Berson, R.G. Foster, and K.-W. Yau. 2003. Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice. Science 299:245–247.Crossref, Medline, CAS, Google Scholar10. Fu, Y., H.-W. Liao, M.T. Do, and K.-W. Yau. 2005. Non-image-forming ocular photoreception in vertebrates. Curr. Opin. Neurobiol. 15:415–422.Crossref, Medline, CAS, Google Scholar11. Jeffery, G. 1998. The retinal pigment epithelium as a developmental regulator of the neural retina. Eye 12:499–503.Crossref, Medline, Google Scholar12. Hattar, S., H.-W. Liao, M. Takao, D.M. Berson, and K.-W. Yau. 2002. Melanopsincontaining retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 295:1065–1070.Crossref, Medline, CAS, Google Scholar13. Plouffe, L. and R.M. Stelmack. 1979. Neuroticism and the effect of stress on the pupillary light reflex. Percept. Mot. Skills 49:635–642.Crossref, Medline, CAS, Google Scholar14. Bi, A., J. Cui, Y.P. Ma, E. Olshevskava, M. Pu, A.M. Dizhoor, and Z.H. Pan. 2006. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 50:23–33.Crossref, Medline, CAS, Google Scholar15. Dinculescu, A., L. Glushakova, S.H. Min, and W.W. Hauswirth. 2005. Adeno-associated virus-vectored gene therapy for retinal disease. Hum. Gene Ther. 16:649–663.Crossref, Medline, CAS, Google Scholar16. Trejo, L.J. and C.M. Cicerone. 1984. Cells in the pretectal olivary nucleus are in the pathway for the direct light reflex of the pupil in the rat. Brain Res. 300:49–62.Crossref, Medline, CAS, Google Scholar17. Clarke, R.J. and H. Ikeda. 1985. Luminance and darkness detectors in the olivary and posterior pretectal nuclei and their relationship to the pupillary light reflex in the rat. I. Studies with steady luminance levels. Exp. Brain Res. 57:224–232.Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future DirectionsInvestigative Opthalmology & Visual Science, Vol. 64, No. 7Nanomedicine and drug delivery to the retina: current status and implications for gene therapy15 September 2022 | Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 395, No. 12Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities3 December 2022 | Journal of Nanobiotechnology, Vol. 20, No. 1Nanoparticle-mediated gene therapy as a novel strategy for the treatment of retinoblastomaColloids and Surfaces B: Biointerfaces, Vol. 220Minicircle Delivery to the Neural Retina as a Gene Therapy Approach2 October 2022 | International Journal of Molecular Sciences, Vol. 23, No. 19Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy19 September 2022 | Pharmaceutics, Vol. 14, No. 9Conjugates of Recombinant Protein‐Based Polymers: Combining Precision with Chemical Diversity23 March 2022 | Advanced NanoBiomed Research, Vol. 2, No. 6Application Prospects for Synthetic Nanoparticles in Optogenetic Retinal Prosthetics20 December 2021 | Journal of Evolutionary Biochemistry and Physiology, Vol. 57, No. 6New Method for Efficient siRNA Delivery in Retina Explants: Reverse Magnetofection3 June 2021 | Bioconjugate Chemistry, Vol. 32, No. 6Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium/Choroid in RabbitsTranslational Vision Science & Technology, Vol. 9, No. 13Pigment Epithelium-Derived Factor Promotes Axon Regeneration and Functional Recovery After Spinal Cord Injury2 May 2019 | Molecular Neurobiology, Vol. 56, No. 11Non-viral-mediated suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of spinal cord dorsal column axons16 July 2018 | Scientific Reports, Vol. 8, No. 1Application of galangin, an active component of Alpinia officinarum Hance (Zingiberaceae), for use in drug-eluting stents15 August 2017 | Scientific Reports, Vol. 7, No. 1Correction of Monogenic and Common Retinal Disorders with Gene Therapy27 January 2017 | Genes, Vol. 8, No. 2Targeting Promoter-Associated Noncoding RNA In Vivo28 March 2017Non-viral gene therapy: Gains and challenges of non-invasive administration methodsJournal of Controlled Release, Vol. 240Nanoparticle‐motivated gene delivery for ophthalmic application22 June 2015 | WIREs Nanomedicine and Nanobiotechnology, Vol. 8, No. 1Nanoparticle-based technologies for retinal gene therapyEuropean Journal of Pharmaceutics and Biopharmaceutics, Vol. 95Targeted Delivery of Nucleic Acid Therapeutics via Nonviral Vectors5 November 2014Vector platforms for gene therapy of inherited retinopathiesProgress in Retinal and Eye Research, Vol. 43Expression of green fluorescent protein in the chicken using in vivo transfection of the piggyBac transposonJournal of Biotechnology, Vol. 173A linear polyethylenimine mediated siRNA-based therapy targeting human epidermal growth factor receptor in SPC-A1 xenograft mice22 February 2013 | Translational Respiratory Medicine, Vol. 1, No. 1RNAi in Ocular Diseases26 April 2013Ocular Gene Delivery Systems Using Ternary Complexes of Plasmid DNA, Polyethylenimine, and Anionic PolymersBiological and Pharmaceutical Bulletin, Vol. 36, No. 1Inhibition of PAX2 Gene Expression by siRNA (Polyethylenimine) in Experimental Model of Obstructive Nephropathy18 October 2012 | Renal Failure, Vol. 34, No. 10Non-viral retinal gene therapy: a review19 September 2011 | Clinical & Experimental Ophthalmology, Vol. 40, No. 1In vivo nucleic acid delivery with PEI and its derivatives: current status and perspectives9 January 2014 | Expert Review of Medical Devices, Vol. 8, No. 2Non-viral siRNA delivery into the mouse retina in vivo1 October 2010 | BMC Ophthalmology, Vol. 10, No. 1Gene delivery to the retina: focus on non-viral approachesDrug Discovery Today, Vol. 14, No. 5-6Efficient siRNA Delivery by the Cationic Liposome DOTAP in Human Hematopoietic Stem Cells Differentiating into Dendritic CellsJournal of Biomedicine and Biotechnology, Vol. 2009Systemic Delivery of DNA or siRNA Mediated by Linear Polyethylenimine (L-PEI) Does Not Induce an Inflammatory Response16 August 2008 | Pharmaceutical Research, Vol. 25, No. 12 Vol. 42, No. 3 STAY CONNECTED Metrics History Received 9 October 2006 Accepted 23 December 2006 Published online 16 May 2018 Published in print March 2007 Information© 2007 Author(s)AcknowledgmentsWe thank members of the Yau laboratory for helpful comments on the manuscript. This work was supported by grant no. EY14596 from the U.S. National Institutes of Health (NIH).Competing Interests StatementThe authors declare no competing interests.PDF download
Referência(s)